ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 102 filers reported holding ESPERION THERAPEUTICS INC NE in Q2 2016. The put-call ratio across all filers is 0.87 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $350,000 | -3.8% | 12,493 | -10.9% | 0.01% | +14.3% |
| Q4 2020 | $364,000 | -25.3% | 14,019 | +7.1% | 0.01% | -46.2% |
| Q3 2020 | $487,000 | +35.7% | 13,091 | +87.0% | 0.01% | +30.0% |
| Q2 2020 | $359,000 | +32.5% | 7,000 | -56.2% | 0.01% | -16.7% |
| Q1 2016 | $271,000 | -23.9% | 16,000 | 0.0% | 0.01% | -52.0% |
| Q4 2015 | $356,000 | +50.8% | 16,000 | +60.0% | 0.02% | +150.0% |
| Q3 2015 | $236,000 | -93.2% | 10,000 | -76.4% | 0.01% | -92.7% |
| Q2 2015 | $3,467,000 | -6.4% | 42,400 | +6.0% | 0.14% | -16.5% |
| Q1 2015 | $3,704,000 | -8.4% | 40,000 | -60.0% | 0.16% | +17.1% |
| Q4 2014 | $4,044,000 | +451.0% | 100,000 | +233.3% | 0.14% | +677.8% |
| Q3 2014 | $734,000 | +54.5% | 30,000 | 0.0% | 0.02% | +80.0% |
| Q2 2014 | $475,000 | +4.6% | 30,000 | 0.0% | 0.01% | +11.1% |
| Q1 2014 | $454,000 | -44.9% | 30,000 | -50.0% | 0.01% | -50.0% |
| Q4 2013 | $824,000 | -78.2% | 60,000 | -70.0% | 0.02% | -56.1% |
| Q3 2013 | $3,772,000 | – | 200,000 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 2,629,835 | $116,685,000 | 25.08% |
| Aviva Holdings Ltd. | 1,200,100 | $53,248,000 | 14.21% |
| Boxer Capital, LLC | 1,375,000 | $61,009,000 | 6.77% |
| BB BIOTECH AG | 3,282,964 | $145,665,000 | 3.86% |
| Rhenman & Partners Asset Management AB | 353,961 | $15,705,000 | 1.57% |
| PFM Health Sciences, LP | 1,970,134 | $87,415,000 | 1.28% |
| Bellevue Group AG | 391,852 | $17,386,000 | 1.10% |
| Pentwater Capital Management LP | 2,351,500 | $104,336,000 | 0.88% |
| Partner Investment Management, L.P. | 25,440 | $1,129,000 | 0.86% |
| SABBY MANAGEMENT, LLC | 100,369 | $4,453,000 | 0.57% |